Advances in the systemic treatment of therapeutic approaches in biliary tract cancer von Mirallas, O., López-Valbuena, D., García-Illescas, D., Fabregat-Franco, C., Verdaguer, H., Tabernero, J., Macarulla, T.

Volltext

Immune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoint in... von Matos Garcia, I., Azaro, A., Viaplana, C., Hierro, C., Martin-Liberal, J., Brana, I., Gardeazabal, I., Gomila, P., Vieito Villar, M., Ochoa De Olza Amat, M., Elez Fernandez, E., Oliveira, M., Oaknin, A., Verdaguer, H., Navarro Mendivil, A., Alsina, M., Tabernero, J., Macarulla Mercade, T., Dienstmann, R., Garralda, E.

Volltext

Neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma. Preliminary results von Busquets, J, Peláez, N, Laquente, B, Verdaguer, H, Secanella, L, Rafecas, A, Torras, J, Serrano, T, Ruiz, S, Ramos, E, Fabregat, J

Volltext

61P Clinical and molecular characterisation of IDH1/2 mutant cholangiocarcinoma von Castet, F., Serra Camprubí, Q., Fabregat-Franco, C., Verdaguer, H., Castillo, G., Tian, T., Macarulla, T.

Volltext

1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical... von Gulley, J., Lacouture, M.E., Spira, A., Mata, H. Verdaguer, Yoo, C., Cho, B.C., Helwig, C., Halady, T., Valencia, C., Bajars, M., Strauss, J., Brownell, I.

Volltext

O-2 Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) von Knox, J., Bazin, I., Oh, D., Zubkov, O., Breder, V., Bai, L., Christie, A., McNamara, M., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K., Park, J., Verdaguer, H., Braconi, C., Ross, P., de Gramont, A., Shroff, R., Zalcberg, J., Palmer, D., Valle, J.

Volltext

59TiP Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) von Knox, J., McNamara, M.G., Goyal, L., Cosgrove, D., Springfeld, C., Sjoquist, K., Park, J.O., Verdaguer, H., Braconi, C., Ross, P., Oh, D-Y., De Gramont, A., Shroff, R.T., Zalcberg, J.R., Palmer, D., Valle, J.W.

Volltext

80TiP Global phase III study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) von Knox, J.J., McNamara, M.G., Goyal, L., Doherty, M., Cosgrove, D., Springfeld, C., Sjoquist, K., Park, J.O., Verdaguer, H., Braconi, C., Ross, P., De Gramont, A., Zalcberg, J.R., Palmer, D., Valle, J.W.

Volltext

1549P Molecular alterations (MA) with potential therapeutic implications in KRAS wild-type (WT) pancreatic cancer patients von Acosta Eyzaguirre, D.A., Verdaguer, H., Buxò, E., Garcia-Alvarez, A., Sardo, E., Hernando, J., Diez Garcia, M., Guardiola, M., Ros Montañá, F.J., Baraibar Argota, I., Saoudi, N., Marmolejo Castaneda, D.H., Aguilar, S., Sierra, A., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Volltext

6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials von Alonso, G., Aguilar, S., Ros Montana, F.J., Verdaguer, H., Callejo Perez, A., Brana, I., Baraibar Argota, I., Iranzo Gomez, P., Saavedra Santa Gadea, O., Salva Ballabrera, F., Acosta Eyzaguirre, D.A., Vieito Villar, M., Garcia Torralba, E., Wornham, N.A., Faull, I., Tabernero, J., Felip, E., Elez, E., Macarulla Mercade, T., Garralda, E.

Volltext

1925P DNA methylation signature for prediction of metastasis and response to multikinase inhibitors of differentiated thyroid carcinoma (DTC) von Hernando, J., Zafon, C., Diez-Villanueva, A., Iglesias, C., Rodriguez, H., Villalmazo, N., Gil, J., Klein-Hesselink, E., Roca, M., Verdaguer, H., Acosta Eyzaguirre, D.A., Diez Garcia, M., Lindo, E., Hernandez-Losa, J., Reverter, J., Puig-Domingo, M., Links, T., Capdevila, J., Jordà, M.

Volltext

1558P Pancreatic cancer (PC) in patients (pts) younger than 50 years: Clinical outcomes and actionable genomic/genetic alterations von Garcia-Alvarez, A., Verdaguer, H., Guardiola, M., Acosta Eyzaguirre, D.A., Buxò, E., Sardo, E., Saoudi, N., Marmolejo Castaneda, D.H., Hernando, J., Diez Garcia, M., Baraibar Argota, I., Ros Montañá, F.J., Sierra, A., Molero, C., Miquel, J.M., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Volltext

573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure von Hernando-Calvo, A., Valdivia, A., Santa Gadea, O. Saavedra, Braña, I., Berché, R., Matos, I., Vieito, M., Pedrazzoli, A.B. Azaro, Casal, G. Alonso, Galvão, V., Garcia, M. Diez, Verdaguer, H., Velez, C. Ortiz, Gonzalez, M., Argota, I. Baraibar, Callejo, A., Couselo, E. Munoz, Tabernero, J., Dienstmann, R., Garralda, E.

Volltext

1545P DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts) von Verdaguer, H., Guardiola, M., Mancuso, F.M., Acosta Eyzaguirre, D.A., Buxò, E., Hernando, J., Diez Garcia, M., Laquente, B., Baraibar Argota, I., Ros Montañá, F.J., Garcia-Alvarez, A., Matito, J., Martin, A., Sierra, A., Villacampa Javierre, G., Molero, C., Miquel, J.M., Vivancos, A., Dienstmann, R., Macarulla Mercadé, T.

Volltext

110PImmune prognostic index (IPI) and hyper-progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in phase I trials (Ph1T): Can lessons from immune checkpoin... von Matos Garcia, I, Azaro, A, Viaplana, C, Hierro, C, Martin-Liberal, J, Brana, I, Gardeazabal, I, Gomila, P, Vieito Villar, M, Ochoa De Olza Amat, M, Elez Fernandez, E, Oliveira, M, Oaknin, A, Verdaguer, H, Navarro Mendivil, A, Alsina, M, Tabernero, J, Macarulla Mercade, T, Dienstmann, R, Garralda, E

Volltext

Molecular, clinical and prognostic characterization of double KRAS/PIK3CA (dKP) mutated metastatic colorectal cancer (mCRC) von Grasselli, J., Elez, E., Martinez, G. Argiles, Sanz-Garcia, E., Macarulla, T., Capdevila, J., Alsina, M., Sauri, T., Hierro, C., Verdaguer, H., Matos, I., Garcia, A., Nuciforo, P., Landolfi, S., Palmer, H. Garcia, Dienstmann, R., Vivancos, A., Tabernero, J.

Volltext

Prognostic impact of KRAS mutation in metastatic (met) pancreatic cancer patients (pts) von Verdaguer, H., Sauri, T., Ruiz, F., Vivancos, A., Nuciforo, P., Capdevila, J., Elez, E., Alsina, M., Martinez, G. Argiles, Hierro, C., Grasselli, J., Matos, I., Tabernero, J., Dienstmann, R., Macarulla, T.

Volltext

51P Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit von Rojas Laimito, K.I., Vieito Villar, M., Fullana Grimalt, B., Berché, R., Hierro Carbo, C., Saavedra Santa Gadea, O., Braña, I., Alonso Casal, G., Galvao de Aguiar, V., Lostes Bardaji, M.J., Oliveira, M., Verdaguer, H., Morales Barrera, R., Garcia Duran, C., Zamora, E., Carles Galceran, J., Macarulla, T., Tabernero, J., Garralda Cabanas, E.

Volltext

P-183 Neoadjuvant treatment in borderline resectable pancreatic adenocarcinoma (PA): A single center series von Verdaguer Mata, H., Laquente, B., Busquets, J., Pelaez, N., Secanella, L., Leiva, D., Ruiz, S., Peiro, I., Lopez Urdiales, R., Serrano, T., Vazquez, S., Calvo, M., Serra, O., Cambray, M., Perez Martin, F.J., Sanchez, C., Galan, M., Fabregat, J.

Volltext

Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights von Dienstmann, Rodrigo, Elez Fernandez, Mª Elena, Argilés Martinez, Guillem, Matos Garcia, Ignacio, Sanz Garcia, Enrique, Ortiz Velez, Carolina, Macarulla Mercadé, Teresa, Capdevila Castillon, Jaume, Alsina Maqueda, Maria, Sauri Nadal, Tamara, Verdaguer Mata, Helena, Ruiz Pace, Fiorella, Viaplana Donato, Cristina, Landolfi, Stefania, García Palmer, Héctor, Nuciforo, Paolo Giovanni, Rodon Ahnert, Jordi, Vivancos Prellezo, Ana, Tabernero Caturla, Josep

Volltext bestellen